A type B hemophiliac treatment acquired the selling approval after the launch of the Benefix 10 years ago
A competing product of the only type B hemophiliac treatment launched in Korea, Benefix, is expected to be launched.
It has been 10 years since the launch of Benefix.
On the 6th, the Ministry of Food and Drug Safety approved the selling rights of the Baxter’s Rixubis
The type B hemophilia is t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
